1.The Future Path for the JKMA.
Journal of the Korean Medical Association 2003;46(1):3-3
No abstract available.
2.Neonatal Hyperbilirubinemia.
Journal of the Korean Pediatric Society 1986;29(5):1-5
No abstract available.
Hyperbilirubinemia, Neonatal*
3.Augmentation Strategies in Obsessive Compulsive Disorder.
Journal of the Korean Society of Biological Psychiatry 1998;5(2):162-165
The serotonin reuptake inhibitors(SRIs) and the serotonin selective reuptake inhibitors(SSRIs) are considered the first choice agents for pharmacologic treatment of obsessive-compulsive disordr(OCD). However, many patients with OCD experience little or no improvement in their symptoms when treated with SRIs or SSRIs. Patients who have experienced a partial or no response to an SRI/SSRI at 10 to 12 weeks are often considered for augmentation strategies. Nearly every class of psychotropic medications has been tried in an open fashion, though augmentation strategies have been somewhat disappointing.
Humans
;
Obsessive-Compulsive Disorder*
;
Serotonin
4.No title in English
Journal of the Korean Medical Association 1997;40(6):778-781
No abstract available.
5.Disorders of the White Blood Cells.
Korean Journal of Pediatrics 2004;47(Suppl 2):S268-S276
No abstract available.
Leukocytes*
6.Current Status and Future Perspective of PET.
Korean Journal of Nuclear Medicine 2002;36(1):1-7
No abstract available.
7.Current Status and Future Perspective of PET.
Korean Journal of Nuclear Medicine 2002;36(1):1-7
No abstract available.
8.Gene Therapy in the Diabetes Mellitus.
Journal of Korean Society of Pediatric Endocrinology 2003;8(2):101-107
No abstract available.
Diabetes Mellitus*
;
Genetic Therapy*
9.Gene Therapy in the Diabetes Mellitus.
Journal of Korean Society of Pediatric Endocrinology 2003;8(2):101-107
No abstract available.
Diabetes Mellitus*
;
Genetic Therapy*
10.DNAse I hypersensitive sites of lung specific transcription factor gene.
Tuberculosis and Respiratory Diseases 2000;48(6):879-886
BACKGROUND: Thyroid Transcription Factor-1(TTF-1) acts as a tissue specific transcription factor in the regulation of lung specific gene expression and as morphogenic protein during lung organogenesis. Currently, there is very little information on the cis-acting sequences and transcription and transcription factors that direct the TTF-1 gene expression. DNAse 1 hypersensitive (DH) sites represent a marker for active or potentially active chromatin and are likely to be especially important in gene regulation, being associated with many DNA sequences that regulate gene expression. It is clear that DH regions correlate with genetic regulatory loci and binding for sequence-specific DNA-binding proteins. METHODS: We have used DH site assays to identify putative distal regulatory elements in H441 lung adenocarcinoma cells, which express the TTF-1 gene and HeLa cells. RESULTS: There are four DH sites 5' of the TTF-1 gene. These sites are located at base pair approximately +150, -450, -800, and -1500 from the start of transcription. CONCLUSION: These data suggest that there may be at least one intragenic site and regulatory region 5' prime to the promotor region.
Adenocarcinoma
;
Base Pairing
;
Base Sequence
;
Chromatin
;
Deoxyribonuclease I*
;
Deoxyribonucleases*
;
DNA-Binding Proteins
;
Gene Expression
;
HeLa Cells
;
Humans
;
Lung*
;
Organogenesis
;
Promoter Regions, Genetic
;
Regulatory Sequences, Nucleic Acid
;
Thyroid Gland
;
Transcription Factors*
Result Analysis
Print
Save
E-mail